Stock analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a "sell" rating on the biotechnology company's stock.
Cyclacel Pharmaceuticals Stock Up 2.7 %
Shares of Cyclacel Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $0.25. The stock had a trading volume of 1,646,104 shares, compared to its average volume of 1,571,771. Cyclacel Pharmaceuticals has a 1 year low of $0.17 and a 1 year high of $3.08. The stock has a 50 day simple moving average of $0.27 and a 200 day simple moving average of $0.38. The company has a market capitalization of $52.08 million, a PE ratio of -0.03 and a beta of 0.15.
Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.04). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million.
Insider Activity at Cyclacel Pharmaceuticals
In related news, CEO David E. Lazar sold 194,628,820 shares of the company's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 68.00% of the company's stock.
About Cyclacel Pharmaceuticals
(
Get Free Report)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Articles
Before you consider Cyclacel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclacel Pharmaceuticals wasn't on the list.
While Cyclacel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
